"The automation provided by the AutoGenomics' INFINITI Analyzer will enhance workflow in our laboratories," said Mark Linder, executive vice president of operations and co-founder of PGXL Labs, in a statement. "With their comprehensive menu of molecular applications in the pharmacogenetics arena, we have found AutoGenomics to be a very suitable partner in meeting our emerging testing needs."  

 

A privately held company based in Vista, Calif., AutoGenomics' technology can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics.

 

"We are excited to partner with PGXL Labs, who have pioneered in bringing the benefits of pharmacogenetics testing to patients across the country," stated Ramanath Vairavan, senior vice president of AutoGenomics. "The versatility of our BioFilmChip Microarray technology allows us to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests. "